positive
BillionToOne, diagnostics firm, files for U.S. IPO after narrowing losses
Molecular diagnostics company BillionToOne filed for a U.S. IPO, showing H1 2025 revenue of $125.5 million (vs. $69 million prior year) and a narrowed net loss of $4.2 million. The firm develops non-invasive prenatal tests and liquid biopsies. Underwriters include J.P. Morgan, Wells Fargo, and William Blair.
Companies:
- BillionToOne
Tags:
- IPO
- healthcare
Reuters• By Sneha Pathak
Explore:Mutual Fund Home
positive
BillionToOne, diagnostics firm, files for U.S. IPO after narrowing losses
Molecular diagnostics company BillionToOne filed for a U.S. IPO, showing H1 2025 revenue of $125.5 million (vs. $69 million prior year) and a narrowed net loss of $4.2 million. The firm develops non-invasive prenatal tests and liquid biopsies. Underwriters include J.P. Morgan, Wells Fargo, and William Blair.
Companies:
- BillionToOne
Tags:
- IPO
- healthcare
Reuters• By Sneha Pathak
Explore:Mutual Fund Home
1 min read
47 words
Diagnostics firm files for U.S. IPO, posts strong revenue growth.
Molecular diagnostics company BillionToOne filed for a U.S. IPO, showing H1 2025 revenue of $125.5 million (vs. $69 million prior year) and a narrowed net loss of $4.2 million. The firm develops non-invasive prenatal tests and liquid biopsies. Underwriters include J.P. Morgan, Wells Fargo, and William Blair.
Molecular diagnostics company BillionToOne filed for a U.S. IPO, showing H1 2025 revenue of $125.5 million (vs. $69 million prior year) and a narrowed net loss of $4.2 million. The firm develops non-invasive prenatal tests and liquid biopsies. Underwriters include J.P. Morgan, Wells Fargo, and William Blair.
Companies:
- BillionToOne
Tags:
- IPO
- healthcare
- IPO
- healthcare
- biotech
- BillionToOne
- diagnostics